AMSTERDAM--(BUSINESS WIRE)--Jan 13, 2025--
Avanzanite Bioscience B.V., a leading commercial-stage specialty pharmaceutical company committed to bringing ground-breaking medicines for rare diseases to market, announced today the appointment of Jason Cameron as Chief Technical Officer (CTO). This move marks a significant step in Avanzanite’s mission to accelerate growth, expand its presence in Europe, and advance the company’s next phase of international partnerships and product launches.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250112229499/en/
As CTO, Cameron will initially focus on the strategic expansion of Avanzanite’s footprint into 26 European countries, driving revenue growth for the current portfolio while also preparing for key new partnerships expected to materialize in 2025.
With over 25 years of experience in pharmaceutical operations, Mr. Cameron brings unparalleled expertise in global product distribution, regulatory compliance, and manufacturing of orphan medicines. His career spans leadership roles at some of the industry’s most innovative biopharmaceutical companies, including Genzyme (Sanofi), Synageva, and Amicus Therapeutics, where he was instrumental in launching more than 17 rare disease treatments.
Prior to joining Avanzanite, Cameron was Chief Operations Officer of Orphan Drug Consulting. Most recently in a corporate role, Mr. Cameron served as Senior Vice President of Technical Operations at Amicus Therapeutics, overseeing global product supply for small molecules, biologics, and gene therapies. Earlier in his career, he played a pivotal role at Genzyme, where he helped establish and scale supply chain operations across Europe and led global commercial supply efforts.
“We are thrilled to welcome Jason to our leadership team, which we proudly refer to as “Avanzanite’s Champions League,” said Adam Plich, Founder and CEO of Avanzanite. “Jason’s deep experience in global pharmaceutical operations, especially in rare disease markets, will be invaluable as we continue to expand our reach and deliver life-changing treatments to patients across Europe and beyond.” Plich continued, "Our long-term vision is to ensure that no patient is left behind when facing a rare disease, and Jason’s expertise and shared commitment to this mission will be instrumental in our success."
In his role, Cameron will oversee key operational functions, including supply chain management, manufacturing, quality assurance, regulatory compliance, and launch management. His leadership will ensure that Avanzanite can continue to provide timely, compliant, and high-quality product supply to patients across multiple regions while laying the groundwork for continued expansion into new markets.
"It’s an exciting opportunity to join Avanzanite and help realize its vision of improving access to orphan medicines for underserved patient populations," said Jason Cameron. "I look forward to working closely with the talented Avanzanite team to strengthen our operational capabilities and further our mission to make a lasting difference in the lives of rare disease patients." Cameron will be based in London, UK.
In 2024, Avanzanite continued its expansion in the European orphan drug market, reaching over 120 patients across 12 markets and generating revenue in six countries. With two authorized medicinal products in its portfolio, the Company is now poised to extend its presence to 26 European countries following the recent authorization of an orphan medicine for acanthamoeba keratitis.
About Avanzanite Bioscience
At Avanzanite Bioscience, we believe the world is full of untapped potential. Our mission is to unlock this potential, bringing life-changing treatments to underserved patient populations and overlooked markets. We are committed to ensuring that no patient is left behind when facing a debilitating rare disease. By acquiring, licensing, and distributing approved or late-stage medicines for rare diseases, we navigate European commercialization hurdles, ensuring that valuable medicines reach the markets and patient populations that need them most.
Founded in 2022 and headquartered in Amsterdam, the Netherlands, Avanzanite operates across Europe, with a growing infrastructure dedicated to serving patients and partners alike.
For more information, visit www.avanzanite.com.
Jason Cameron, Chief Technical Officer, Avanzanite Bioscience (Photo: Business Wire)
OKLAHOMA CITY (AP) — Shai Gilgeous-Alexander isn't scoring the way he usually does, but the Oklahoma City Thunder are still winning the way they normally do.
Gilgeous-Alexander, the reigning NBA MVP, averaged 31.1 points during the regular season. In the Western Conference semifinals against the Los Angeles Lakers, he is averaging 20 points and taking only 14 shots per game.
Oklahoma City has still won the first two games by an average of 18 points. Gilgeous-Alexander and Chet Holmgren each scored 22 points, and the defending champion Thunder beat the Lakers 125-107 on Thursday night.
Ajay Mitchell, starting in place of injured Jalen Williams, is averaging 19 points on 50% shooting in the series for Oklahoma City.
“I think the coaching staff does a good job at just getting all of us ready,” said Mitchell, a second-year guard. "And we have a lot of competitors. Like, everyone’s a competitor on our team. So every time the lights are bright, everyone’s ready to go.”
Holmgren is the leading scorer for the Thunder in the best-of-seven series with 23 points per game. The 2026 All-Star also is averaging 10.5 rebounds and 2.5 blocks.
Jared McCain, a midseason acquisition from the Philadelphia 76ers, barely played in the first round against Phoenix but has averaged 15 points and made 8 of 10 3-pointers in the series.
“He goes in there, stays in character, stays aggressive," Thunder coach Mark Daigneault said. "He’s going to shoot the next shot. He makes the right plays, plays inside the team. He competes defensively, has had good defensive possessions for us. And he was huge tonight. You need that in a playoff series.”
The Lakers again were without scoring champion Luka Doncic, who is out indefinitely with a strained left hamstring. They also were missing forward Jarred Vanderbilt, the reserve forward who dislocated the pinkie on his right hand during the second quarter of Game 1. The Lakers had three players finish with five fouls, limiting their aggressiveness late in the game.
Los Angeles guard Austin Reaves, who struggled with his shot in Game 1, scored 31 points on 10-for-16 shooting in Game 2. LeBron James, coming off a 27-point effort in Game 1, followed that up with 23.
With the Lakers up 63-61 early in the third quarter, Gilgeous-Alexander got tied up with Reaves and was called for his fourth foul. Upon review, it was upgraded to a flagrant 1 for Gilgeous-Alexander's follow through. Oklahoma City's Alex Caruso was called for a technical foul as the situation was being sorted out.
Gilgeous-Alexander left the game with the Lakers up 65-61, but the Thunder rallied and took control without him. On a fast break, Holmgren found a trailing Jaylin Williams, who hit a 3-pointer and was fouled. His free throw put the Thunder up 85-74.
The Thunder outscored the Lakers 32-15 while Gilgeous-Alexander was out in the third quarter to take a 93-80 lead into the fourth.
“It was amazing," Gilgeous-Alexander said. “They strung together stops, they’re playing the right way offensively and things are going their way. Full confidence in those guys. They know how to win basketball games. And we've proven that. They’ve proven that no matter who’s on the floor, they know how to get the job done. And they just did it again tonight."
The Lakers cut Oklahoma City's lead to five in the fourth quarter before the Thunder pulled away again.
Los Angeles will host Game 3 on Saturday.
“We just stuck with it,” Holmgren said. “It’s the game of basketball. It’s not always going to go your way. It’s about how you respond. And this team has proven many times that we know how to respond. And we did so tonight.”
This story has been corrected to show that Shai Gilgeous-Alexander is averaging 20, not 19, points per game against the Lakers.
AP NBA: https://apnews.com/hub/NBA
Oklahoma City Thunder's Chet Holmgren (7) shoots over Los Angeles Lakers' Austin Reaves (15) in the second half of Game 2 in a second-round NBA basketball playoffs series Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)
Oklahoma City Thunder guard Ajay Mitchell, front, works for a shot as Los Angeles Lakers' Austin Reaves, rear, defends in the second half of Game 2 in a second-round NBA basketball playoffs series Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)
Los Angeles Lakers' LeBron James stands on the court in the second half of Game 2 in a second-round NBA basketball playoffs series against the Oklahoma City Thunder Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)
Oklahoma City Thunder guard Shai Gilgeous-Alexander (2) drives to the basket past Los Angeles Lakers' Deandre Ayton (5) and LeBron James, rear, in the second half of Game 2 in a second-round NBA basketball playoffs series Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)
Oklahoma City Thunder center Chet Holmgren (7) works to the basket against Los Angeles Lakers forward Rui Hachimura (28) in the second half of Game 2 in a second-round NBA basketball playoffs series Thursday, May 7, 2026, in Oklahoma City. (AP Photo/Nate Billings)
